CagrilintidevsDanuglipron

Cagrilintide is a long-acting analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells after meals. Native amylin plays a crucial but often overlooked role in metabolic regulation — it signals satiety, slows gastric emptying, and suppresses post-meal glucagon secretion through mechanisms entirely distinct from the GLP-1 pathway.

Cagrilintide activates amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptors are concentrated in the area postrema and the nucleus tractus solitarius in the brainstem — regions outside the blood-brain barrier that can directly sense circulating peptides. Activation of these neurons triggers ascending satiety signals to the hypothalamus, reducing meal size and food-seeking behavior through pathways that are neuroanatomically separate from GLP-1 signaling.

This distinct mechanism is why cagrilintide produces additive appetite suppression when combined with semaglutide (as CagriSema) — the two peptides target different populations of neurons within the brain's appetite control circuitry. Cagrilintide has been engineered with acylation modifications that enable albumin binding, extending its half-life from minutes (native amylin) to approximately one week, making it suitable for weekly subcutaneous dosing.

Danuglipron (PF-06882961) is a non-peptide small molecule GLP-1 receptor agonist designed for oral administration without the food and water restrictions that limit Rybelsus (oral semaglutide). As a small molecule rather than a peptide, it is not destroyed by gastric acid or proteolytic enzymes, allowing flexible oral dosing.

The molecule binds the GLP-1 receptor outside the orthosteric peptide-binding pocket, producing biased agonism that activates the same downstream G-protein signalling as native GLP-1 — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite regulation through hypothalamic and brainstem GLP-1 receptors. The key engineering feature is its short pharmacokinetic profile, with a half-life around 6-9 hours, designed for twice-daily dosing rather than once-daily exposure to limit peak plasma concentrations and improve gastrointestinal tolerability.

In Phase 2 obesity and type 2 diabetes trials, danuglipron produced meaningful weight loss and HbA1c reductions, validating the small-molecule oral GLP-1 concept. However, gastrointestinal tolerability was problematic — over 70% of trial participants experienced nausea — and the program was ultimately discontinued by Pfizer in 2025 following a single case of suspected drug-induced liver injury in a healthy volunteer. Pfizer pivoted to alternative oral GLP-1 candidates with reduced hepatic exposure profiles. Danuglipron remains a high-search-volume topic because of its prominent failure and because it set early benchmarks for what oral small-molecule GLP-1 drugs (notably orforglipron from Eli Lilly) needed to beat to succeed.